查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197715

神經介入設備市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Neurointerventional Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，神經介入設備市場的複合年增長率預計為 7.7%。

COVID-19 爆發將以多種方式影響神經介入設備市場，從需要限制重症監護病房 (ICU) 病床和通風場所，到推遲擇期和/或複雜病例。 此外，分析表明，在大流行期間和之後，神經乾預的管理存在很大差異。 例如，根據 Cardiovascular Revascularization Medicine 2022 年 7 月的一份報告，需要在血管介入領域進行更多研究，以確定因 COVID-19 大流行而停止的介入性血管試驗的總體影響。假設是 然而，由於醫療機構的重新開放、COVID-19患者的減少以及COVID-19後血管介入的後續試驗，預計市場將迅速復蘇。

市場增長的主要驅動因素是患者人數的增加、產品開發和商業化的持續進行，以及神經血管治療領域研究活動的增加。

神經介入設備由專注於中樞神經系統 (CNS) 領域的醫療保健專業人員使用。 它通常由神經放射學家、神經外科醫生和尋求血管內方法治療中樞神經系統血管疾病的神經學家進行。 受試者中與中樞神經系統相關的血管疾病的負擔主要驅動設備的使用。 根據 2022 年 6 月更新的 WSO 數據，到今年年底，約有 1220 萬人 (12,224,551) 將經歷中風。 顱內動脈瘤，也稱為腦動脈瘤或腦動脈瘤，是大腦中動脈壁的膨脹和薄弱區域。 2022 年 4 月更新的英國國家醫療服務體系 (NHS) 數據顯示，腦動脈瘤的患病率可高達每 20 人中就有 1 人，而且腦動脈瘤會影響任何人，無論年齡大小。它會發生，但最常見見於40歲以上的人。 此外，根據 2022 年 1 月腦動脈瘤基金會的更新，估計有 650 萬美國人患有未破裂的腦動脈瘤。 在美國，每年約有 30,000 人患有腦動脈瘤破裂。 每 18 分鐘就有一個腦動脈瘤破裂。 隨著越來越多的中樞神經和血管疾病患者來到醫療機構，對神經介入設備的需求預計會增長。

同樣，新設備的開發和批准也將在研究期間推動市場的增長。 例如，2021 年 4 月，美敦力 (Medtronic) 的 Pipeline Flex Embolization Device 屏蔽技術獲得美國 FDA 批准。 Pipeline Flex 栓塞裝置可轉移腦動脈瘤的血流。

在分析期間，這些因素充分促進了市場的增長。 然而，嚴格的法規和熟練的神經外科醫生短缺是該市場增長的主要限制。

神經介入設備的市場趨勢

預計在預測期內，缺血性中風部分將佔市場的主要份額

缺血性中風的特徵是大腦的一部分突然失去血液循環以及相關的神經功能惡化。 對該細分市場產生積極影響的關鍵因素包括缺血性中風發病率的增加以及市場上各個主要參與者的發展。

例如，根據 WSO 的 2022 年全球中風情況說明書，每年發生超過 760 萬例新的缺血性中風。 在全球範圍內，超過 62% 的中風是缺血性中風。 這表明每年需要使用神經介入設備進行適當的神經介入治療的病例數都在顯著增加。 因此，在預測期內，缺血性中風等血管疾病發病率的增加將推動神經介入設備市場的發展。

同樣，在研究期間，用於缺血性中風的設備的最新發展推動了市場增長。 例如，2022 年 6 月，Rapid Medical 在 DISTALS 試驗中招募了第一位患者。 這項研究是有史以來第一個 FDA 研究設備豁免（ IDE ），使用最小和最可調節的取栓設備 TIGERTRIEVER 13 測試機械取栓術在遠端中風中的安全性和有效性。 這是一項考試。 神經介入設備的用途是巨大的，廣泛的用途導致動脈疾病的矯正。 同樣，2022年2月，微創神通有限公司（以下簡稱微創神通）自主研發的Neurohawk支架取栓器（以下簡稱Neurohawk）獲得國家藥監局上市許可。 Neurohawk是微創神通推出的治療急性缺血性腦卒中的血栓支架取栓器。

因此，鑑於上述事實，預計研究市場在預測期內將會增長。

預計在預測期內北美將佔據很大的市場份額

北美地區的貢獻在美國是最高的，這是該地區在全球佔據主導地位的一個因素。 由於許多地方擁有先進的醫療保健基礎設施以及許多與醫院有聯繫的醫療設備製造商，北美主要推動了該市場的增長。

根據疾病預防控制中心 2022 年 4 月發布的數據，超過 795,000 名美國人中風。 每年，這些病例中會發現 610,000 例新病例。 大約 87% 的中風是缺血性中風，其中流向大腦的血液受阻。 因此，該地區中風患者數量的增加將增加對神經介入設備進行適當管理的需求，從而有助於預測期內市場的增長。

此外，新設備的批准和發布也將有助於市場增長。 例如，2022 年 2 月，CERENOVUS 推出了 EMBOGUARD，這是一種用於血管內治療的下一代球囊引導導管，包括急性缺血性中風患者。 EMBOGUARD 球囊引導導管旨在通過在 MT 手術期間局部控制血流來優化血栓清除。 因此，每一個新設備的批准和發布都有助於該地區的市場增長。

因此，上述所有因素都有望在預測期內推動市場增長。

神經介入器械市場競爭者分析

神經介入設備市場競爭適中，由幾家大型企業組成。 這些公司在通過神經介入設備治療血管內疾病方面看到了持續的增長機會。 該領域的主要公司包括雅培、強生服務公司（CERENOVUS）、美敦力、史賽克、Penumbra, Inc.、MicroPort Scientific Corporation、Terumo Corporation 和 W. L. Gore & Associates, Inc.。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 增加目標患者的數量
    • 持續的產品開發和商業化
    • 激活神經血管治療領域的研究活動
  • 市場製約因素
    • 嚴格監管
    • 缺乏熟練的神經外科醫生
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（按價值計算的市場規模：百萬美元）

  • 按產品分類
    • 動脈瘤捲繞和栓塞裝置
    • 腦球囊血管成形術和支架置入系統
    • 神經取栓裝置
    • 其他設備
  • 通過申請
    • 缺血性中風
    • 腦動脈瘤
    • 動靜脈畸形/瘺管
    • 其他疾病
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Abbott
    • Johnson & Johnson Services, Inc（CERENOVUS）
    • Medtronic
    • MicroPort Scientific Corporation
    • Penumbra, Inc.
    • Stryker
    • Terumo Corporation
    • W. L. Gore & Associates, Inc.

第7章 市場機會今後動向

簡介目錄
Product Code: 68181

The neurointerventional devices market is expected to register a CAGR of 7.7% over the forecast period.

The outbreak of COVID-19 affected the neurointerventional devices market in several ways, as it limited the intensive care unit (ICU) beds and ventilation sites owing to the necessity of postponing elective and/or complex cases. Moreover, as per the analysis, there were considerable variations in the management of neuro interventions during and after the pandemic. For instance, as per the report published by Cardiovascular Revascularization Medicine in July 2022, to ascertain the overall effect on vascular intervention trials halted by the COVID-19 pandemic, more research is required in the field of vascular intervention. Hence, the market is expected to rapidly rebound to pre-pandemic levels nonetheless, as a result of the restart of all healthcare facilities, a drop in COVID-19 cases, and follow-up trials on vascular intervention after COVID-19.

The major factors contributing to the growth of the market are the increasing target patient population, ongoing product development and commercialization, and rising research activities in the field of neurovascular therapies.

Neurointerventional devices are used by medical professionals specializing in the domain of the central nervous system (CNS). It is usually done by neuroradiologists, neurosurgeons, and neurologists exploring the endovascular approach to treat the vascular diseases of the central nervous system. The burden of vascular diseases associated with the central nervous system in the target population primarily drives the usage of devices. According to WSO data updated in June 2022, about 12.2 million (12,224,551) people will experience a stroke by the end of the year. In addition, the intracranial aneurysm, also known as a cerebral or brain aneurysm, is a bulging, weakened area in the wall of an artery in the brain. According to data from the National Health Service (NHS), England, updated in April 2022, the prevalence of brain aneurysms could be as high as 1 in 20 people, and brain aneurysms can develop in anyone at any age, but are more common in people over the age of 40. Furthermore, according to updated data from the Brain Aneurysm Foundation in January 2022, an estimated 6.5 million Americans have an unruptured brain aneurysm. About 30,000 people in the United States suffer a brain aneurysm rupture each year. A brain aneurysm ruptures every 18 minutes. The consistently high volume of patients with CNS vascular diseases approaching healthcare facilities is expected to drive the demand for neurointerventional devices.

Similarly, the new device developments and approvals will help the market grow during the study period. For instance, in April 2021, Medtronic received approval from the US FDA for the Pipeline Flex Embolization Device with Shield Technology. The Pipeline Flex Embolization Device diverts blood flow away from a brain aneurysm.

Such factors are altogether contributing to the market's growth over the analysis period. However, the stringent regulations and dearth of skilled neurosurgeons are the primary limitations to the growth of the studied market.

Neurointerventional Devices Market Trends

Ischemic Stroke Segment is Expected to Hold Major Share of the Market Over the Forecast Period

Ischemic stroke is characterized by the sudden loss of blood circulation to an area of the brain, resulting in a corresponding loss of neurologic function. The major factors that positively impact the segment include the increase in the incidence of ischemic stroke and the developments made by various major players in the market.

For instance, as per the WSO's Global Stroke Fact Sheet 2022, there are over 7.6 million new ischemic strokes each year. Globally, over 62% of all incident strokes are ischaemic strokes. This shows a significant rise in cases every year that need proper neurointerventions through neurointerventional devices. Thus, the increase in the incidence of vascular diseases like ischaemic stroke drives the neurointerventional devices market over the forecast period.

Similarly, the recent developments in the devices used for ischemic stroke drove the market growth during the study period. For instance, in June 2022, Rapid Medical enrolled the first patient in the DISTALS Study. The trial is the first-ever FDA investigational device exemption (IDE) trial to examine the safety and effectiveness of mechanical thrombectomy in distal stroke with TIGERTRIEVER 13, the smallest and most adjustable thrombectomy device. With a wide range of applications linked to arterial-based disease correction, there is significant usage of neurointerventional devices. Similarly, in February 2022, MicroPort NeuroTech Limited (MicroPort NeuroTech) received marketing approval from the NMPA for its self-developed Neurohawk Stent Thrombectomy Device (Neurohawk). The Neurohawk is the clot stent retriever launched by MicroPort NeuroTech for acute ischemic stroke treatment.

Thus, given the above-mentioned facts, the studied market is expected to grow over the forecast period.

North America is Expected to Hold a Significant Share in the Market Over the Forecast Period

The United States contributes the most to the North American region and is responsible for the dominance of the region across the world. North America, with its advanced healthcare infrastructure across the majority of places and the presence of many medical device companies well-connected with hospitals, primarily boosts the growth of this market.

According to the statistics published by the CDC in April 2022, more than 795,000 Americans have strokes. Each year, 610,000 of these instances are discovered to be new. About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked. Hence, the increase in stroke cases in the region increases the demand for neurointerventional devices for proper management, which helps in the growth of the market during the forecast period.

Furthermore, new device approvals and launches also help the market grow. For instance, in February 2022, CERENOVUS launched EMBOGUARD, a next-generation balloon guide catheter to be used in endovascular procedures, including those for patients with acute ischemic stroke. The EMBOGUARD balloon guide catheter is designed to optimize the removal of clots by controlling blood flow locally during MT procedures. Thus, all the new device approvals and launches help the market grow in the region.

Thus, all the aforementioned factors are expected to boost the market's growth over the forecast period.

Neurointerventional Devices Market Competitor Analysis

The neurointerventional devices market is moderately competitive and consists of several major players. The companies have identified consistent growth opportunities in the treatment of endovascular-based diseases via neurointerventional devices. Some of the major companies in this segment include Abbott, Johnson & Johnson Services, Inc. (CERENOVUS), Medtronic, Stryker, Penumbra, Inc., MicroPort Scientific Corporation, Terumo Corporation, and W. L. Gore & Associates, Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions & Market Defination
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Target Patient Population
    • 4.2.2 Ongoing Product Development and Commercialization
    • 4.2.3 Rising Research Activities in the Field of Neurovascular Therapies
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations
    • 4.3.2 Dearth of Skilled Neurosurgeons
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - by USD million)

  • 5.1 By Product
    • 5.1.1 Aneurysm Coiling & Embolization Devices
    • 5.1.2 Cerebral Balloon Angioplasty and Stenting Systems
    • 5.1.3 Neurothrombectomy Devices
    • 5.1.4 Other Devices
  • 5.2 By Application
    • 5.2.1 Ischemic Stroke
    • 5.2.2 Cerebral Aneurysms
    • 5.2.3 Arteriovenous Malformation and Fistulas
    • 5.2.4 Other Diseases
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott
    • 6.1.2 Johnson & Johnson Services, Inc (CERENOVUS)
    • 6.1.3 Medtronic
    • 6.1.4 MicroPort Scientific Corporation
    • 6.1.5 Penumbra, Inc.
    • 6.1.6 Stryker
    • 6.1.7 Terumo Corporation
    • 6.1.8 W. L. Gore & Associates, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS